FK-664
FK-664 is a leukotriene inhibitor. FK-664 enhances ventricular contractility and shortens the time to peak tension in cardiac cells. FK-664 reduces mean circulating pressure (MCP) in a canine model of heart failure. FK-664 can be used in research on cardiovascular diseases such as heart failure.
For research use only. We do not sell to patients.
- CAS No.: 94936-90-0
- Formula: C24H29N3O3
- Molecular Weight:407.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Leukotriene Receptor Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 94936-90-0
-
Molecular Weight 407.51
-
Formula C24H29N3O3
-
SMILES
O=C1N(C)/C(C=C(N1CC)C2=CC(OC)=C(OC)C=C2)=N/C3=C(C)C=C(C)C=C3C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Kodama I, et al. Electrophysiological effects of FK664, a new cardiotonic agent, on preparations from guinea pig ventricle and from rabbit sino-atrial node. Cardiovasc Res. 1989 May;23(5):369-77. [Content Brief]
[2]. Sudo Y,et al. The effect of FK664, a new cardiovascular drug, on systemic capacitance vessels in anesthetized dogs. Life Sci. 1992;51(25):PL261-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FK-664 Related Classifications
HY-19020 Related Classifications
Powered by Bioz